Business Wire

Takeda Expands Oncology Research, Demonstrating Commitment to Patient Community at 15th International Symposium on Myelodysplastic Syndromes

7.5.2019 17:00:00 EEST | Business Wire | Press release

Share

Takeda Pharmaceutical Company Limited [TSE: 4502 / NYSE: TAK] today announced that it will present a total of five company-sponsored poster presentations, as well as an oral pipeline symposium, at the 15th International Symposium on Myelodysplastic Syndromes taking place in Copenhagen, Denmark from May 8-11, 2019. Takeda’s presentations will highlight the company’s investigations into the epidemiology, prognosis and patient reported outcomes for higher-risk myelodysplastic syndromes (HR-MDS) and the related conditions – chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) – to achieve a deep understanding of these rare cancers and the needs of this patient community.

“We are excited to join the MDS community at this upcoming meeting where we will share key findings around Takeda’s research in HR-MDS, CMML and AML,” said Hui Huang, PhD, Head, Oncology Global Outcomes Research at Takeda. “For over a decade, there has been little advancement in treatment options for people living with HR-MDS and CMML, despite poor patient outcomes. Takeda’s investment in this wide-ranging global outcomes research directly captures patient input to better understand these cancers, as well as AML, and the impact on their lives. These findings are an important aspect of our work as we strive to bring new treatment options to patients.”

At this year’s International Symposium on Myelodysplastic Syndromes, Takeda will present results from a variety of innovative research studies. These results are the first global systematic review of HR-MDS and CMML on incidence and prevalence, including the risk of transformation to AML. The results will also quantify the disease burden, discuss the difficulties associated with diagnosis and underscore the significant unmet need of this patient population. Some of this research was conducted in collaboration with the MDS Foundation – an international non-profit advocacy organization whose mission is to support and educate patients and healthcare providers with innovative research into the fields of MDS, AML and related myeloid neoplasms.

Five Takeda Oncology-sponsored abstracts were accepted for poster presentation, as well as an oral pipeline symposium during MDS 2019:

Note: All times listed are in Central European Standard Time

For more information, the MDS 2019 program is available here: https://mds.kenes.com/2019/scientific/scientific-program#.XJosUihKhdg

About Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia

Myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) are rare forms of blood cancer that are caused by irregular blood cell production within the bone marrow. As a result of this irregular production, a person with MDS, CMML or AML does not have enough normal red blood cells, white blood cells and/or platelets in circulation. Symptoms for MDS, CMML and AML are often vague and related to low blood counts, and may include fatigue, shortness of breath, easy bruising or bleeding, loss of appetite, weakness, pale skin, fever and frequent or severe infections.

There are several classifications of MDS – lower risk to higher-risk – determined by blood counts, blast counts, mutations and cytogenetics. Higher-risk disease is defined as intermediate, high or very high risk on the International Prognostic Scoring System – Revised (IPSS-R), and these patients often have a poorer prognosis. In some cases, MDS and CMML can progress into AML.

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience and Rare Diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.

For more information, visit https://www.takeda.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Takeda Pharmaceutical Company Limited

Japanese Media
Kazumi Kobayashi
kazumi.kobayashi@takeda.com
+81 (0) 3-3278-2095

Media outside Japan
Victoria von Rinteln
victoria.vonrinteln@takeda.com
+1-617-444-4391

About Business Wire

Business Wire
Business Wire



http://www.businesswire.com

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HyperLight Introduces 400G-per-lane TFLN PICs on its Chiplet™ Platform for Next-Generation AI Interconnects17.3.2026 14:03:00 EET | Press release

HyperLight Corporation (“HyperLight”), creator of the TFLN Chiplet™ Platform, today announced the availability of 400G-per-lane thin-film lithium niobate (TFLN) photonic integrated circuits (PICs) designed for next-generation AI networking infrastructure. The new PIC family delivers low insertion loss, low drive voltage operation, and exceptional electro-optic bandwidth, enabling energy-efficient and high-performance 400G-per-lane optical links. The transition to 400G-per-lane is a critical step for future AI infrastructure, enabling higher interconnect bandwidth and improved system density. HyperLight’s 400G-per-lane TFLN PICs provide the large electro-optic bandwidth and low-voltage operation required to support these next-generation optical links, where bandwidth, signal integrity, and power efficiency are increasingly challenging for electronic ICs to sustain. HyperLight’s TFLN devices combine high modulation efficiency with extremely low optical loss, enabling transmitter architec

Klarna Smashes 1 Million Merchants Milestone17.3.2026 14:00:00 EET | Press release

Klarna, the global digital bank and flexible payments provider, has surpassed 1 million merchants globally. Klarna has grown the number of merchants offering its payment methods by 47% in the past year, adding 285,000 merchants in 2025, and more than 115,000 in the final quarter alone. The growth is being driven by Klarna's expanding agreements with the world's leading payment service providers, giving merchants around the world easier access to Klarna at checkout. Leisure, Sport & Hobby is now Klarna's fastest-growing merchant category, up 91% YoY in February 2026, reflecting growing consumer demand for flexible payments in wellness and fitness. David Sykes, Chief Commercial Officer at Klarna: "Home repairs, a new couch, salon appointments, gym memberships - these are facts of life for most people, but the way they pay for them hasn't kept up. Reaching 1 million merchants is a reflection of how deeply embedded Klarna is becoming in everyday money management, and the acceleration acros

1.5 Billion Women Miss Essential Preventive Tests, Despite Uptick in Global Screening Rates17.3.2026 14:00:00 EET | Press release

Global women’s health leader Hologic, Inc. (Nasdaq: HOLX) today released data showing that while testing for some health conditions has risen among women globally, a vast screening gap remains. Over half of women and girls aged 15 and older — an estimated 1.5 billion women — were not tested for cancer, high blood pressure, diabetes or sexually transmitted infections (STIs) in the past year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317786907/en/ Hologic Global Women's Health Index Fifth Edition The data are part of the fifth edition of the Hologic Global Women’s Health Index developed in partnership with Gallup. Based on an annual survey of 145,000 people in 144 countries and territories, the Index tracks progress in women’s health and well-being worldwide. Five years of Index data show that the proportion of women screened for key preventable conditions has increased in some countries, but at the global level, scree

Armis Warns Cyberwarfare Threats at Global Tipping Point as AI Accelerates Escalation17.3.2026 14:00:00 EET | Press release

Armis, the cyber exposure management & security company, is warning that cyberwarfare threats have reached a global pressure-cooker moment. As emerging technologies accelerate cyber operations and geopolitical tensions worsen, attackers are increasingly targeting the infrastructure, information, and systems that underpin global stability. “Geopolitical tensions, AI acceleration, and unresolved security gaps are colliding, bringing the state of cyberwarfare to a boiling point,” said Nadir Izrael, CTO and Co-Founder of Armis. “Cyberwarfare is now a constant condition; attackers are operating at machine speed, while too many organizations are still trying to defend themselves with assumptions and structures built for a very different threat landscape. Organizational leaders must heed the call and immediately enhance their proactive cybersecurity operations before it’s too late.” New findings from Armis Labs’ fourth annual global Cyberwarfare report, A World Under Pressure: Cyberwarfare in

Riskified Launches Dispute Resolve for Shopify to Help Merchants Automate Chargeback Management and Recover Lost Revenue17.3.2026 14:00:00 EET | Press release

Riskified (NYSE: RSKD), a leader in ecommerce fraud and risk intelligence, today announced the release of Dispute Resolve for Shopify. This specialized offering is designed to transform the often-complex, highly manual chargeback management process into a streamlined, automated engine, enabling Shopify merchants to recover revenue with greater efficiency and with less manual effort. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317398106/en/ Many merchants are currently forced to log into multiple payment gateway portals to view fraud and non-fraud chargebacks, manually copy/paste and organize compelling evidence, and build custom reporting to assess win-rate performance. Dispute Resolve provides a single source of truth through a real-time dashboard that automatically syncs with a wide variety of payment gateways, providing instant clarity into dispute performance and significantly improving workflows. The solution incl

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye